ClinicalTrials.gg

Program

PRMT5 Inhibitor AZD3470

Its studies are mostly in Lymphoma, led by AstraZeneca.

Furthest: phase 2, since Oct 19, 20232 company-led studies, 2 open or runningNext primary completion: Dec 4, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca22 open or runningphase 2since Oct 19, 2023Oct 19, 2023Dec 4, 2028phase 2 · NCT06130553
  • Named in AstraZeneca’s own pipeline as AZD3470, phase 2, as of Oct 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 19, 2023First study: phase 2 study in Advanced Solid Tumors That Are MTAP DeficientFirst studyNCT06130553 · 334 planned · United States, Australia, China and more
  2. Nov 2, 2023Phase 2 study in LymphomaNCT06137144 · 161 planned · United States, Australia, Brazil and more

Ahead

  1. Dec 4, 2028Primary completion: phase 2 study in Advanced Solid Tumors That Are MTAP DeficientNCT06130553
  2. May 3, 2029Primary completion: phase 2 study in LymphomaNCT06137144

TargetBeta

“An orally bioavailable second generation methylthioadenosine (MTA)-selective small molecule inhibitor of the protein arginine methyltransferase 5 (PRMT5), with potential antineoplastic activity. Upon oral administration, PRMT5 inhibitor AZD3470 inhibits PRMT5 in the presence of MTA, thereby speci…”NCIt, read by Claude

Other programs on PRMT5

ProgramCompanyFurthest phaseStudies
navlimetostatBristol-Myers Squibbphase 310
JBI-778rulejubilant-therapeutics-india-limitedphase 22
PRMT5 Inhibitor TNG456ruletango-therapeutics-incphase 21
PRMT5 Inhibitor BAY 3713372ruleBayerphase 21
onametostatruleJohnson & Johnsonphase 12
PRMT5 Inhibitor SH3765ruleNanjing Sanhome Pharmaceuticalphase 12
PRMT5 Inhibitor BGB-58067ruleBeOne Medicinesphase 12
PRMT5 Inhibitor IDE892ruleideaya-biosciencesphase 11
PEP08rulepharmaenginephase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06137144Lymphoma · United States, Australia, Brazil and more2RecruitingMay 3, 2029161
NCT06130553Advanced Solid Tumors That Are MTAP Deficient · United States, Australia, China and more2RecruitingDec 4, 2028334

How it is read

Names in the registry

  • “AZD3470”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.